Investigating the causes and progression of neurocognitive disorders in Thailand
Investigating Neurocognitive Disorders Epidemiology
This study is trying to understand how neurocognitive disorders like dementia progress in people in Thailand by looking at blood samples and cognitive tests from both healthy individuals and those with memory issues.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 990 (estimated) |
| Ages | 35 Years and up |
| Sex | All |
| Sponsor | King Chulalongkorn Memorial Hospital Academic / other |
| Locations | 1 site (Pathum Wan, Bangkok) |
| Trial ID | NCT06375213 on ClinicalTrials.gov |
What this trial studies
This observational study aims to predict the progression of neurocognitive disorders, including dementia and Alzheimer's disease, in the Thai population. It will evaluate plasma phosphorylated tau levels and cognitive test scores to develop a predictive model for cognitive decline. Participants, including healthy individuals and those with mild cognitive impairment or late-onset dementia, will undergo biospecimen collection, structured interviews, and cognitive examinations, with follow-up visits scheduled annually or biennially. The study also seeks to understand the socioeconomic impact of these disorders and establish a biorepository for future research.
Who should consider this trial
Good fit: Ideal candidates include cognitively healthy individuals, those with mild cognitive impairment, and patients with late-onset dementia who are proficient in Thai.
Not a fit: Patients with significant neurological or uncontrolled psychiatric illnesses, or those with unstable systemic conditions, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved early diagnosis and management of neurocognitive disorders, enhancing patient outcomes.
How similar studies have performed: Other studies have shown success in using biomarkers for predicting cognitive decline, making this approach promising yet still novel in the Thai context.
Eligibility criteria
Show full inclusion / exclusion criteria
1. Cognitively Healthy Individuals INCLUSION CRITERIA * Demonstrate normal cognitive function within the expected range on objective cognitive tests. * Proficient in speaking and understanding Thai without the need for a translator to participate. EXCLUSION CRITERIA * Significant neurological or uncontrolled psychiatric illness. * Significant unstable systemic condition or end-stage organ failure that affects study participation. 2. Mild Cognitive Impairment INCLUSION CRITERIA * Display impaired/abnormal performance on objective cognitive tests. * Does not meet criteria for dementia per NIA-AA (or major neurocognitive disorder per DSM-5). * Proficient in speaking and understanding Thai without the need for a translator to participate. EXCLUSION CRITERIA * Significant neurological or uncontrolled psychiatric illness. * Significant unstable systemic condition or end-stage organ failure that affects study participation. 3. Late Onset Dementia INCLUSION CRITERIA * Display impaired/abnormal performance on objective cognitive tests. * Meets criteria for dementia per NIA-AA (or major neurocognitive disorder per DSM-5), including dementia due to Alzheimer's disease or other causes. * Begins to experience symptoms, identified by the physician as a part of dementia continuum, occurring after the age of 65. * Proficient in speaking and understanding Thai without the need for a translator to participate. EXCLUSION CRITERIA * Significant neurological or uncontrolled psychiatric illness. * Significant unstable systemic condition or end-stage organ failure that affects study participation. 4. Early Onset Dementia INCLUSION CRITERIA * Display impaired/abnormal performance on objective cognitive tests. * Meets criteria for dementia per NIA-AA (or major neurocognitive disorder per DSM-5), including dementia due to Alzheimer's disease or other causes. * Begins to experience symptoms, identified by the physician as a part of dementia continuum, occurring before the age of 65. * Proficient in speaking and understanding Thai without the need for a translator to participate. EXCLUSION CRITERIA * Significant neurological or uncontrolled psychiatric illness. * Significant unstable systemic condition or end-stage organ failure that affects study participation.
Where this trial is running
Pathum Wan, Bangkok
- King Chulalongkorn Memorial Hospital — Pathum Wan, Bangkok, Thailand (Recruiting)
Study contacts
- Principal investigator: Thiravat Hemachudha, M.D. — Chulalongkorn University
- Study coordinator: Poosanu Thanapornsangsuth, M.D.
- Email: poosanu.t@chula.ac.th
- Phone: +66 (0)2 2564000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.